Skip to content
  • Sunday, 26 July 2026
  • 1:44 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • GSK Secures US Approval for Jideytro in ROS1-Positive Lung Cancer, Entering Competitive Market
Pharmaceutical R&D

GSK Secures US Approval for Jideytro in ROS1-Positive Lung Cancer, Entering Competitive Market

Teuku Ryan Jul 23, 2026 0

Just days after finalizing a monumental $10.6 billion acquisition of Nuvalent, a move that significantly bolsters its oncology pipeline, GlaxoSmithKline…

Read More
Pharmaceutical R&D

J&J raises FY26 outlook following positive Q2 – Pharmaceutical Technology

Teuku Ryan Jul 16, 2026 0

Johnson & Johnson (J&J) announced robust second-quarter (Q2) revenues totaling approximately $25.3 billion, marking a significant 6.6% increase year-over-year (YoY).…

Read More
Neuroscience & Brain Research

Yale Study Reveals That Significant Cognitive and Physical Gains Are Common in Older Adults Driven by Positive Beliefs About Aging

Rifan Muazin Jun 28, 2026 0

The traditional narrative of aging has long been characterized as a period of inevitable and irreversible decline, where both the…

Read More
Pharmaceutical R&D

ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma – Pharmaceutical Technology

Teuku Ryan Jun 2, 2026 0

The rapidly evolving landscape of multiple myeloma treatment is witnessing a pivotal moment with the emergence of in vivo chimeric…

Read More
Pharmaceutical R&D

Novo Nordisk’s Wegovy Poised for Significant European Expansion Following Positive CHMP Opinions on Oral and High-Dose Injectable Formulations

Teuku Ryan May 27, 2026 0

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has delivered two pivotal positive opinions, paving…

Read More
Pharmaceutical R&D

European Commission Approves Keytruda Combination Therapy for PD-L1-Positive Platinum-Resistant Ovarian Cancer

Teuku Ryan Apr 6, 2026 0

The European Commission (EC) has granted approval for Keytruda (pembrolizumab) in combination with paclitaxel, with or without bevacizumab, as a…

Read More
Unlocking Peak Performance: Advanced Optimization for Local Language Models with OllamaScience News: A Century of Empowering Public Understanding of ScienceTWiV 1287: Ancient Herpesviruses and Modern DementiaTWiV 1293: The enemy of your parasite is your friend
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ